InnovAge reported adjusted EBITDA of $94.571 million for the fiscal year ended June 30, 2026, up from $34.462 million in the prior year. Management expects investments to support Business and results over the longer term, although those activities increase expenses as a percentage of Revenue in the short term.
Key Highlights
- InnovAge reported $94.571 million in adjusted EBITDA for fiscal 2026, compared with $34.462 million for fiscal 2025.
- Medicaid represented 56% of capitation revenue, while Medicare accounted for 44% during fiscal 2026.
- Cumulative actual paid claims for fiscal 2026 were $302.366 million.
InnovAge Holding Corp. (NASDAQ: INNV) reported adjusted EBITDA of $94.571 million for the fiscal year ended June 30, 2026, compared with $34.462 million in the previous fiscal year. The company expects investments made in its operations to support business and results over the longer term. Those investments increased expenses as a percentage of revenue in the short term. The filing reports claims activity, provider costs and litigation-related charges. Medicaid supplied 56% of capitation revenue, while Medicare contributed 44%.
Fiscal-Year Operating Metrics
Capitation revenue is paid monthly on a per-participant basis by Medicare, Medicaid, Veterans Affairs and private-pay sources. During fiscal 2026, Medicaid accounted for 56% of the company’s capitation revenue and Medicare accounted for 44%, with Veterans Affairs, private pay and other sources representing less than 1%. Claims incurred for fiscal 2026 were recorded at $365.304 million. Cumulative actual incurred claims for that fiscal year stood at $358.504 million, while cumulative actual paid claims were $302.366 million. The filing lists external provider costs of $449.843 million and pharmacy expense of $84.539 million.
Charges Behind Fiscal Results
Business optimization costs for fiscal 2026 included $3.5 million related to organizational restructuring and executive severance. The company’s business optimization initiatives also covered investments designed to enhance technology and compliance systems and improve the efficiency and effectiveness of operations. Adjusted EBITDA was $94.571 million for fiscal 2026, compared with $34.462 million for fiscal 2025.
Longer-Term Investment Outlook
InnovAge anticipates that its investments will positively affect the business and results of operations over the longer term. In the short term, the activities increase expenses as a percentage of revenue. The investments relate to technology, compliance systems and operational efficiency initiatives. Capitation revenue is subject to estimates and later adjustments as final settlements are determined. Risk-adjustment reconciliation revenue reflects differences between estimated per-participant capitation revenue and amounts ultimately determined by CMS.
Operating Risks To Monitor
CMS measures participant risk-adjustment scores twice per year. Reconciliation payments historically occur between June and July, although their timing is determined by CMS. The filing states that PACE state contracts are renewed annually each June 30 in states other than California and Pennsylvania.




Please wait processing your request...